An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences.
The biopharma industry is intensely competitive, and companies must go to great lengths to gain any commercial edge. However, it is also an industry that sees more failure than success. Pre-clinical investigations run into dead ends. Clinical trials don’t meet their endpoints. Even drugs that make it to market often fail to generate substantial revenue.
To complicate matters, the commercial environment is becoming increasingly constrained. The USA's Inflation Reduction Act and other emerging revenue restraints are tightening margins across the industry. As a result, corporate efficiency is becoming an increasingly valuable competitive advantage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze